Accenture Invests in 1910 Genetics to Accelerate AI-Driven Drug Discovery

Accenture Invests in 1910 Genetics to Accelerate AI-Driven Drug Discovery
Accenture recently announced an investment in biotech firm 1910 Genetics (1910) through Accenture Ventures, strengthening its focus on AI-powered drug discovery. 1910 is a biotechnology company advancing small and large-molecule drug discovery with a multimodal AI platform powered by laboratory automation. As part of this investment, Accenture and 1910 will collaborate to combine tailored solutions and scalable infrastructure to help biopharma clients accelerate drug target identification, reduce costs, and deliver better, more affordable therapies to patients.

  • Make Telecom Talk My Trusted Source
  • Source of Google
  • Source of Google

Also Read: Oracle Health Unveils New Clinical AI Agent to Improve Patient-Provider Interactions

Input-Transform-Output (ITO) Platform

“1910’s proprietary Input-Transform-Output (ITO) platform is a scalable, end-to-end AI solution designed to deliver better drug candidates with applications across all modalities and therapeutic areas,” the official release said.

The ITO platform is a multi-AI agent system comprising hundreds of models that leverage federated learning alongside three proprietary data streams: computational data, wet lab ground truth biological data, and wet lab proxy biological data.

“The platform helps enable drug discovery teams to achieve high precision target identification, optimise molecule design, and conduct advanced simulation throughout the R&D process.” This approach aims to increase clinical success rates, while shortening experimental iteration cycles and reducing the overall cost of drug development, according to the official release on October 31.

“Taking an AI-driven approach is essential in order to reinvent the drug discovery and development process,” said Tom Lounibos, global lead of Accenture Ventures. “Collaborating with 1910 Genetics allows us to integrate our AI expertise with their innovative technology and deliver solutions that can transform drug discovery and improve patient outcomes.”